Molecular hydrogen for outpatients with Covid-19 (Hydro-Covid): a phase 3, randomised, triple-blinded, adaptive, placebo-controlled, multicentre trial
In 2 patients with mild-to-moderate, due to its antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties, molecular hydrogen (H₂ ) is potentially a novel therapeutic gas for acute coronavirus disease 2019 (COVID-19) patients. These findings add human evidence that helps define the outcomes that…
Read Article